This application is for the Gynecologic Oncology Group (GOG) CCOP Research Base. The GOG is a nonprofit organization promoting excellence in clinical, translational and basic scientific research in the field of gynecologic malignancies. As the premier world-wide clinical trial group in the prevention and treatment of gynecologic cancers, the GOG has developed an active and productive cancer and prevention control program (CPC). The CPC committee was initiated by the GOG in 1995 and has grown to 46 members with an Executive committee developed in 2005 to better guide the development, activation and completion of phase lib and III clinical trials and observational and clinical translational studies. The CPC Executive Committee membership includes the CPC Committee Co-Chairs, ex-officio NCI-Division of Cancer Prevention representatives (Drs. Minasian and Kelaghan), prevention members (Drs. Byron and Garcia), CCOP members (Drs, Rodriguez and Method), members of the Committees on Experimental Medicine and Healthcare Outcome Research and representatives of the GOG Statistical and Data Center and Administrative Office. Meeting by conference call six times yearly, the CPC Executive Committee oversees the work of the CPC disease-site and discipline subcommittees. The GOG affiliate network is made up of primarily community based institutions working under the supervision of a full member institution. In addition, the GOG serves as a research base for 31 CCOPs and 155 CCOP components that provide national clinical trials in many areas of very limited access. The CCOP leaders have direct input to the research directions of Method leads GOG-0224. The CCOPs provide access to patients, and patients in turn are provided access to high quality clinical trial. In addition to providing a strong environment of cancer prevention and treatment research to the CCOP community, the GOG provides, at each of its meetings, cutting edge, in depth workshops and seminars concerning the scientific underpinning for high quality gynecologic and pre cancer management.
Access to oncology clinical trials is a major concern for patients throughout the United States;and adequate accrual to answer important and relevant questions is critical to an ever improving standard of care for patients. Through its network of CCOP institutions, the GOG is able to provide cancer prevention and control trials leading to education and prevention programs designed to foster earlier detection of gynecologic malignancies, suitable early treatment, and eventual elimination of these cancers as a public health risk.
|(2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675|
|(2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401|
|Hibler, Elizabeth A; Kauderer, James; Greene, Mark H et al. (2016) Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study. Menopause 23:1228-1232|
|(2016) Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18:64|
|Chan, John K; Brady, Mark F; Penson, Richard T et al. (2016) Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med 374:738-48|
|Coleman, Robert L; Sill, Michael W; Thaker, Premal H et al. (2015) A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 138:30-5|
|Blein, Sophie; Bardel, Claire; Danjean, Vincent et al. (2015) An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res 17:61|
|Minasian, Lori M; Tangen, Catherine M; Wickerham, D Lawrence (2015) Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol 42:748-63|
|Blanco, Ignacio; Kuchenbaecker, Karoline; Cuadras, Daniel et al. (2015) Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One 10:e0120020|
|McMeekin, D Scott; Sill, Michael W; Walker, Joan L et al. (2015) A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 138:36-40|
Showing the most recent 10 out of 31 publications